Pancreatic Cancer Research

ResearcherUniversity of IowaActive in the last 2 years

Carlos H.F. Chan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3656-2470; OpenAlex author ID A5056949839. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
3
Collaborators
34
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 7 papers

Papers 16

  1. Impact of Neoadjuvant Approach and Tumor Response on Survival in Pancreatic Adenocarcinoma. Last author DOI 10.1002/jso.70329↗
  2. Factors associated with mortality in pancreatic adenocarcinoma patients achieving pathologic complete response after neoadjuvant therapy. Last author DOI 10.1016/j.amjsurg.2026.117093↗
  3. CFTR modulation alter pancreatic cancer cell growth and signaling: implications for cancer risk in cystic fibrosis. Co-author DOI 10.1016/j.jcf.2026.08.012↗
  4. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. Last author DOI 10.1093/oncolo/oyag416↗
  5. Impact of biliary fungal contamination on outcomes after pancreaticoduodenectomy for pancreatic cancer. Last author DOI 10.3389/fonc.2026.1776853↗
  6. Irreversible electroporation associated with improved overall survival vs standard of care for stage 3 pancreatic ductal adenocarcinoma Last author DOI 10.64898/2026.05.19.26353144↗
  7. Transcriptomic Profiling and Demographic Analysis of Appalachian Patients with Pancreatic Ductal Adenocarcinoma using the Purity Independent Subtyping of Tumor… Co-author DOI 10.64898/2026.09.22.26363302↗
  8. Potentiating the effect of immunotherapy in pancreatic cancer using gas-entrapping materials. Co-author DOI 10.1016/j.biomaterials.2025.123097↗
  9. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  10. Role of Diagnostic Laparoscopy During Pancreatic Cancer Surgery in the Modern Era. Last author DOI 10.1016/j.jss.2024.03.035↗
  11. Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Regis… Last author DOI 10.3390/cancers16233894↗
  12. Retrospective study of testosterone deficiency and symptom burden in patients with pancreatic cancer. Co-author DOI 10.21037/tau-22-684↗
  13. Machine-learning based investigation of prognostic indicators for oncological outcome of pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fonc.2022.895515↗
  14. Effect of bacterial contamination in bile on pancreatic cancer cell survival. Last author DOI 10.1016/j.surg.2020.09.029↗
  15. Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0213576↗
  16. [Pancreatic cancer: the surgeon's point of view]. First author PMID 22188961↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Patricio Marcelo Polanco · 3 shared papers, 2024–2026 · strength 0.74
  2. Sean Patrick Cleary · 3 shared papers, 2024–2026 · strength 0.74
  3. Michael D. Kluger · 3 shared papers, 2024–2026 · strength 0.74
  4. Rebekah Ruth White · 3 shared papers, 2024–2026 · strength 0.74
  5. Robert C.G. Martin · 3 shared papers, 2024–2026 · strength 0.74
  6. Hassan Aziz · 2 shared papers, 2026 · strength 0.57
  7. Mohammed O. Suraju · 2 shared papers, 2026 · strength 0.57
  8. Govindarajan Narayanan · 2 shared papers, 2026 · strength 0.54
  9. Chet W. Hammill · 2 shared papers, 2026 · strength 0.54
  10. David A. Iannitti · 2 shared papers, 2024–2026 · strength 0.47
  11. Jeremy Chang · 2 shared papers, 2022–2024 · strength 0.41
  12. Jeremy Chang · 1 shared paper, 2026 · strength 0.32
  13. Andrew W Norris · 1 shared paper, 2026 · strength 0.30
  14. Yunxia O’Malley · 1 shared paper, 2026 · strength 0.30
  15. Prabhat C. Goswami · 1 shared paper, 2026 · strength 0.30
  16. Aliye Uç · 1 shared paper, 2026 · strength 0.30
  17. Hannah R. Shrader · 2 shared papers, 2021–2022 · strength 0.29
  18. Deepak Vadehra · 1 shared paper, 2026 · strength 0.23
  19. Justin B. Miller · 1 shared paper, 2026 · strength 0.23
  20. Michael J. Cavnar · 1 shared paper, 2026 · strength 0.23
  21. Chelsey Mckenna Williams · 1 shared paper, 2026 · strength 0.23
  22. Ashish Manne · 1 shared paper, 2026 · strength 0.23
  23. Reema Anil Patel · 1 shared paper, 2026 · strength 0.23
  24. Joseph Kim · 1 shared paper, 2026 · strength 0.23
  25. Dae Won Kim · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.